Showing results (11-20 of 37) with videos related to
Sort By:
Pageof 4
The American Journal of Managed Care|September 3, 2014
Comparison between guideline-preferred and nonpreferred first-line HIV antiretroviral therapyStephen S Johnston, Timothy Juday, Amanda M Farr, et al.Journal of Medical Economics|September 4, 2016
Public health impact of comprehensive hepatitis C screening and treatment in the French baby-boomer populationOlivier Ethgen, Yuri Sanchez Gonzalez, Grégoire Jeanblanc, et al.Clinicoeconomics and Outcomes Research : CEOR|September 17, 2013
Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the USTimothy Juday, Todd Correll, Ayanna Anene, et al.Expert Opinion on Pharmacotherapy|September 14, 2012
Adherence and persistence with non-nucleoside reverse transcriptase inhibitor-based antiretroviral regimensCharu Taneja, Timothy Juday, Larry Gertzog, et al.Journal of Comparative Effectiveness Research|September 28, 2019
Costs, exacerbations and pneumonia after initiating combination tiotropium olodaterol versus triple therapy for chronic obstructive pulmonary diseaseSwetha R Palli, Ami R Buikema, Mary DuCharme, et al.Journal of General Internal Medicine|October 28, 2010
Adherence to chronic hepatitis B treatment guideline recommendations for laboratory monitoring of patients who are not receiving antiviral treatmentTimothy Juday, Hong Tang, Melissa Harris, et al.Journal of Medical Economics|February 4, 2011
Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United StatesMichael S Broder, Eunice Y Chang, Tanya G K Bentley, et al.Medical Decision Making : an International Journal of the Society for Medical Decision Making|April 23, 2011
Using administrative claims data to estimate virologic failure rates among human immunodeficiency virus-infected patients with antiretroviral regimen switchesMichael S Broder, Timothy Juday, Eunice Y Chang, et al.Health Affairs (Project Hope)|March 5, 2014
Early HIV treatment led to life expectancy gains valued at $80 billion for people infected in 1996-2009John A Romley, Timothy Juday, Matthew D Solomon, et al.The International Journal of Neuroscience|May 26, 2020
Challenges and opportunities in insomnia disorderMeaghan Roach, Timothy Juday, Rifat Tuly, et al.Pageof 4